---
schema_version: "secwatch.filing_event.v1"
accession: "0001779372-22-000005"
form_type: "8-K"
ticker: "BEAT"
cik: "0001779372"
company_name: "HeartBeam, Inc."
filed_at: "2022-02-02T23:59:59+00:00"
generated_at: "2026-06-27T12:26:22.174240+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# HeartBeam partners with LIVMOR for RPM platform; terminates Ximedica deal

## Summary
- Partnered with LIVMOR to build HeartBeam-branded version of LIVMOR's FDA-cleared Halo+ RPM portal for physicians and patients.
- Terminated prior development agreement with Ximedica, effective January 31, 2022, to proceed with LIVMOR partnership.
- Customized HeartBeam Platform intended to support FDA submission of heart attack detection software for ED settings later in 2022.
- Development fees paid in two equal installments; term of three years with automatic renewal unless terminated.
- Senior executives of both companies will supervise the project; LIVMOR provides regulatory support for FDA clearance.

## SEC filing metadata
- accession: 0001779372-22-000005
- form_type: 8-K
- ticker: BEAT
- cik: 0001779372
- company_name: HeartBeam, Inc.
- filed_at: 2022-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1779372/000177937222000005/0001779372-22-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1779372/000177937222000005/beat-20220131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001779372-22-000005
- JSON: https://secwatch.observer/filing/0001779372-22-000005.json
- Plain text: https://secwatch.observer/filing/0001779372-22-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.